Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech sector has found its footing again after several difficult years. The equal-weighted S&P Biotechnology ETF (XBI) has staged an impressive rebound, helped by a revival in risk appetite, ...